Bifunctional cysteine-engineered CAR-T cells enable thiol-mediated targeting to overcome antigen escape in B cell lymphoma
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies; however, durable remissions remain limited due to antigen-negative cancer relapse, where tumor cells downregulate or lose the targeted antigen to evade immune recognition. To address this cha...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 7, 2025
|
| In: |
ACS central science
Year: 2025, Jahrgang: 11, Heft: 10, Pages: 1852-1861 |
| ISSN: | 2374-7951 |
| DOI: | 10.1021/acscentsci.5c00816 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1021/acscentsci.5c00816
|
| Verfasserangaben: | Jost Lühle, Simon Krost, Felix Goerdeler, Aina Valentí, Elena Shanin, Christian Seitz, Peter H. Seeberger, and Oren Moscovitz |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1945959916 | ||
| 003 | DE-627 | ||
| 005 | 20251212100937.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251212s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acscentsci.5c00816 |2 doi | |
| 035 | |a (DE-627)1945959916 | ||
| 035 | |a (DE-599)KXP1945959916 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Lühle, Jost |e VerfasserIn |0 (DE-588)1383394024 |0 (DE-627)1944419012 |4 aut | |
| 245 | 1 | 0 | |a Bifunctional cysteine-engineered CAR-T cells enable thiol-mediated targeting to overcome antigen escape in B cell lymphoma |c Jost Lühle, Simon Krost, Felix Goerdeler, Aina Valentí, Elena Shanin, Christian Seitz, Peter H. Seeberger, and Oren Moscovitz |
| 264 | 1 | |c August 7, 2025 | |
| 300 | |b Illustrationen, Diagramme | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.12.2025 | ||
| 520 | |a Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies; however, durable remissions remain limited due to antigen-negative cancer relapse, where tumor cells downregulate or lose the targeted antigen to evade immune recognition. To address this challenge, we developed cysteine-engineered CAR (CysCAR) T cells that redirect T cells to target cancer cells based on extracellular redox imbalances and the altered thiol/disulfide ratios, a marker we identified on B cell lymphomas. Here, we show that CysCAR-T cells, engineered with different cysteine-modified antibody fragments, exhibit a potent and specific cytotoxicity in vitro across various B cell lymphoma (BCL) subtypes, even in antigen escape models. Moreover, by integrating cysteine engineering with clinically used anti-CD19 CAR-T cells, we enabled simultaneous targeting of CD19 and altered redox states on BCL, potentially reducing the risk of antigen escape. In a pilot in vivo study, these bifunctional CD19-CysCAR-T cells suppressed tumor growth and prolonged survival of BCL-bearing mice without inducing systemic toxicity. Given that aberrant exofacial redox states are a hallmark of multiple cancers, our findings suggest a promising strategy to enhance the efficacy of anti-CD19 CAR-T cell therapy, overcome antigen escape, and reduce tumor relapse in BCL, with potential applicability to other malignancies. | ||
| 700 | 1 | |a Krost, Simon |e VerfasserIn |0 (DE-588)1384157298 |0 (DE-627)1945961627 |4 aut | |
| 700 | 1 | |a Goerdeler, Felix |e VerfasserIn |4 aut | |
| 700 | 1 | |a Valentí, Aina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shanin, Elena |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seitz, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seeberger, Peter H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moscovitz, Oren |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a American Chemical Society |t ACS central science |d Washington, DC : ACS Publ., 2015 |g 11(2025), 10, Seite 1852-1861 |h Online-Ressource |w (DE-627)821520776 |w (DE-600)2816030-7 |w (DE-576)428518885 |x 2374-7951 |7 nnas |
| 773 | 1 | 8 | |g volume:11 |g year:2025 |g number:10 |g pages:1852-1861 |g extent:10 |a Bifunctional cysteine-engineered CAR-T cells enable thiol-mediated targeting to overcome antigen escape in B cell lymphoma |
| 856 | 4 | 0 | |u https://doi.org/10.1021/acscentsci.5c00816 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20251212 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1384157298 |a Krost, Simon |m 1384157298:Krost, Simon |d 910000 |d 910500 |e 910000PK1384157298 |e 910500PK1384157298 |k 0/910000/ |k 1/910000/910500/ |p 2 | ||
| 999 | |a KXP-PPN1945959916 |e 4826798229 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"note":["Gesehen am 15.12.17"],"disp":"American Chemical SocietyACS central science","type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"display":"American Chemical Society","roleDisplay":"VerfasserIn","role":"aut"}],"language":["eng"],"recId":"821520776","pubHistory":["1.2015 -"],"titleAlt":[{"title":"Central science"}],"part":{"year":"2025","pages":"1852-1861","issue":"10","volume":"11","text":"11(2025), 10, Seite 1852-1861","extent":"10"},"title":[{"title":"ACS central science","title_sort":"ACS central science"}],"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["American Chemical Society"]},"origin":[{"publisherPlace":"Washington, DC","dateIssuedDisp":"2015-","publisher":"ACS Publ.","dateIssuedKey":"2015"}],"id":{"eki":["821520776"],"zdb":["2816030-7"],"issn":["2374-7951"]}}],"physDesc":[{"noteIll":"Illustrationen, Diagramme","extent":"10 S."}],"name":{"displayForm":["Jost Lühle, Simon Krost, Felix Goerdeler, Aina Valentí, Elena Shanin, Christian Seitz, Peter H. Seeberger, and Oren Moscovitz"]},"id":{"doi":["10.1021/acscentsci.5c00816"],"eki":["1945959916"]},"origin":[{"dateIssuedDisp":"August 7, 2025","dateIssuedKey":"2025"}],"language":["eng"],"recId":"1945959916","type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 12.12.2025"],"person":[{"roleDisplay":"VerfasserIn","display":"Lühle, Jost","role":"aut","family":"Lühle","given":"Jost"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Krost, Simon","given":"Simon","family":"Krost"},{"roleDisplay":"VerfasserIn","display":"Goerdeler, Felix","role":"aut","family":"Goerdeler","given":"Felix"},{"family":"Valentí","given":"Aina","display":"Valentí, Aina","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Elena","family":"Shanin","role":"aut","display":"Shanin, Elena","roleDisplay":"VerfasserIn"},{"display":"Seitz, Christian","roleDisplay":"VerfasserIn","role":"aut","family":"Seitz","given":"Christian"},{"roleDisplay":"VerfasserIn","display":"Seeberger, Peter H.","role":"aut","family":"Seeberger","given":"Peter H."},{"family":"Moscovitz","given":"Oren","roleDisplay":"VerfasserIn","display":"Moscovitz, Oren","role":"aut"}],"title":[{"title":"Bifunctional cysteine-engineered CAR-T cells enable thiol-mediated targeting to overcome antigen escape in B cell lymphoma","title_sort":"Bifunctional cysteine-engineered CAR-T cells enable thiol-mediated targeting to overcome antigen escape in B cell lymphoma"}]} | ||
| SRT | |a LUEHLEJOSTBIFUNCTION7202 | ||